Black checkmark with a sparkle and a curved line underneath on a white background.
Company

POSITRON CORP

Ticker
POSC
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include management stock option grants, multiple PET-CT system orders from cardiology practices, capital raises to support growth, and strategic partnerships to expand market presence and product offerings.

Recent developments:
  • On November 5, 2025, Positron granted options to purchase 5,150,000 shares of common stock to management under its 2021 Equity Incentive Plan, fully vested and exercisable through 2030 [S1].
  • The company secured multiple PET-CT orders from leading nuclear cardiologist practices, indicating ongoing market demand [N1].
  • Positron raised $2 million to expand market presence and growth initiatives, supporting its strategic objectives [N1].
  • The company announced its transition to a reporting SEC company, enhancing transparency and regulatory compliance [N1].
  • Positron entered an industry partnership agreement with MedAxiom to expand cardiac PET-CT offerings [N1].
Overview

Positron Corporation, incorporated in 1983 and headquartered in North Tonawanda, NY, develops and markets PET and PET-CT imaging systems with a primary focus on cardiac PET imaging used in nuclear cardiology. The company aims to improve diagnosis and management of cardiovascular disease by providing advanced molecular imaging solutions that combine proprietary hardware with clinical and technical support services. Positron's product lineup includes dedicated PET systems and the upcoming Affinity™ PET-CT 4D 64-slice system designed for cardiology, oncology, and neurology applications. The company collaborates with Shenyang Intelligent Nuclear Medical Technology Co., a Neusoft Medical Systems subsidiary, for manufacturing and distribution in North America. Positron targets mid-sized hospitals, outpatient centers, and cardiology practices, offering flexible financing and service agreements to facilitate adoption. The company competes with large OEMs but differentiates through focused cardiac expertise, integrated support, and cost-effective pricing. Financial data as of September 2026 indicates modest revenue and ongoing net losses, with liquidity ratios below 1 [S1][S2].

Executive summary

Positron Corporation is a medical technology company specializing in PET and PET-CT imaging systems primarily for cardiac applications. The company emphasizes cost-effective, high-performance molecular imaging solutions supported by comprehensive clinical and technical services. Its strategic partnership with Neusoft Medical Systems supports product development and manufacturing. Financial data as of 2026-09-30 shows limited cash reserves and a current ratio below 1, with recent quarterly revenue of $102,667 and a net loss of $971,982. The company is positioned to address the transition from SPECT to PET-CT imaging in nuclear cardiology through competitive pricing and integrated support services [S1][S2]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for POSC

Bull case model:

Positron's focused expertise in cardiac PET imaging and its development of next-generation PET-CT systems position it to capitalize on the growing clinical adoption of PET-based nuclear cardiology. Its competitive pricing relative to major OEMs and flexible financing options may enable broader market penetration, especially among mid-sized hospitals and outpatient centers. The company's integrated service and support offerings enhance customer retention and system uptime, potentially driving repeat business. Strategic partnerships and ongoing product innovation could support expansion into oncology and neurology imaging applications, diversifying revenue streams [S1].

Bear case model:

Positron operates in a competitive market dominated by large multinational OEMs with greater financial and technical resources, which may limit its market share growth. The company's financials show limited liquidity and ongoing net losses, indicating potential challenges in sustaining operations and funding growth initiatives. Barriers such as high capital costs, operational complexity, and the need for specialized expertise may constrain adoption of its systems. The transition from SPECT to PET-CT imaging, while underway, may be slower than anticipated due to reimbursement, regulatory, or clinical practice factors. Dependence on partnerships for manufacturing and distribution introduces execution risks [S1][S2].

Moat:

Positron's moat is based on its specialized focus on cardiac PET and PET-CT imaging, proprietary imaging systems optimized for cardiovascular applications, and integrated clinical and technical support services that facilitate adoption and operational efficiency. Its strategic partnership with Neusoft Medical Systems enhances product development and manufacturing capabilities. The company's flexible financing models and targeted market approach to mid-sized hospitals and outpatient centers create barriers for competitors focused on larger institutions. Additionally, Positron's emphasis on cost-effective solutions positions it to participate in the structural transition from SPECT to PET-CT imaging in nuclear cardiology, supported by clinical acceptance and reimbursement dynamics [S1].

Risks overview
Risks summary
The primary risks for Positron Corporation include competitive pressures from larger OEMs, financial constraints with ongoing losses and limited liquidity, and market adoption challenges related to capital costs and operational complexity.
Risks details:

• Competitive Pressure: Positron faces competition from large OEMs like GE HealthCare, Philips Healthcare, and Siemens Healthineers with greater resources and broader product portfolios.
• Financial Constraints: The company reported a net loss and has limited cash reserves with liquidity ratios below 1, which may impact its ability to invest in growth and operations.
• Market Adoption Barriers: High capital costs, operational complexity, and specialized expertise requirements may limit adoption of PET and PET-CT systems, especially in smaller healthcare settings.
• Execution Risks: Reliance on strategic partnerships for manufacturing and distribution could pose risks if collaborations do not perform as expected or regulatory approvals are delayed.

FINAL FORECAST FOR POSC

Final take one line
Positron Corporation exhibits very high visibility with detailed disclosures on its specialized cardiac PET imaging business, supported by recent strategic developments and financial data.
Final take 12 to 24 month view

Business trends: The company is positioned to participate in the transition from SPECT to PET-CT imaging in nuclear cardiology, expanding into oncology and neurology applications.
Execution milestones: Introduction of the Affinity™ PET-CT 4D system, securing orders from cardiology practices, capital raises, and strategic partnerships to enhance market presence.
Key risks: Competitive pressures from larger OEMs, financial constraints with limited liquidity and ongoing losses, and barriers to adoption due to capital costs and operational complexity.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Positron Corporation is a medical technology company incorporated in Texas in 1983 with headquarters in North Tonawanda, New York [S1].
  • The company develops, manufactures, and sells PET and PET-CT imaging systems focused primarily on cardiac PET imaging used in nuclear cardiology for diagnosis and management of cardiovascular disease [S1].
  • Positron's product portfolio includes dedicated PET systems and next-generation PET-CT platforms, including the upcoming Affinity™ PET-CT 4D 64-slice system designed for cardiology, oncology, and neurology applications [S1].
  • The company collaborates with Shenyang Intelligent Nuclear Medical Technology Co., a subsidiary of Neusoft Medical Systems, for product development, manufacturing, and distribution, with exclusive North American rights for PET and PET-CT scanners [S1].
  • Positron offers comprehensive clinical and technical support services including training, remote diagnostics, maintenance, and flexible financing options such as rental and lease-to-own programs to facilitate adoption [S1].
  • The company targets mid-sized hospitals, outpatient imaging centers, and cardiology practices, emphasizing cost-effective, high-performance imaging solutions to support the transition from SPECT to PET-CT imaging in nuclear cardiology [S1].
  • Positron's systems are designed to improve diagnostic accuracy, workflow efficiency, patient outcomes, and reduce total cost of ownership, with reported system uptime historically exceeding 98% [S1].
  • The company faces competition from large multinational OEMs like GE HealthCare, Philips Healthcare, and Siemens Healthineers but differentiates through focused cardiac PET expertise and integrated service models [S1].
  • Financial snapshot as of 2026-09-30 shows cash and equivalents of $28,000, current assets of $2,879,008, current liabilities of $4,079,547, resulting in a current ratio of 0.71 and cash ratio of 0.01 [S2].
  • For the quarter ended 2026-09-30, Positron reported revenue of $102,667 and a net loss of $971,982 with basic and diluted EPS of -$0.03 [S2].
  • The company has recently granted stock options to management and continues to secure orders and partnerships to expand market presence [S1].
  • Recent press releases highlight multiple PET-CT orders from leading cardiology practices, capital raises to support growth initiatives, and strategic partnerships to enhance product offerings and market reach [N1].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-14 | www.nasdaq.com | Can the Anthropic IPO Save the AI Rally? | https://www.nasdaq.com/articles/can-anthropic-ipo-save-ai-rally
  • N2 | 2026-11-14 | www.nasdaq.com | Lucara Diamond Corp. Q3 Earnings Summary | https://www.nasdaq.com/articles/lucara-diamond-corp-q3-earnings-summary
  • N3 | 2026-11-14 | www.nasdaq.com | Crown Point Energy Inc Q3 Loss Narrows | https://www.nasdaq.com/articles/crown-point-energy-inc-q3-loss-narrows
  • N4 | 2026-11-14 | www.nasdaq.com | Corn Firm into the Weekend as Export Business Picks Up | https://www.nasdaq.com/articles/corn-firm-weekend-export-business-picks
  • N5 | 2026-11-14 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
  • N6 | 2026-11-14 | www.nasdaq.com | Hogs Post Gains Across the Board on Friday | https://www.nasdaq.com/articles/hogs-post-gains-across-board-friday
  • N7 | 2026-08-15 | www.nasdaq.com | Prediction: These 3 Artificial Intelligence (AI) Stocks Will Rise More than 30% Before 2026 Is Over | https://www.nasdaq.com/articles/prediction-these-3-artificial-intelligence-ai-stocks-will-rise-more-30-2026-over
  • N8 | 2026-08-15 | www.nasdaq.com | Breakfast News: Mastercard's CEO Speaks | https://www.nasdaq.com/articles/breakfast-news-mastercards-ceo-speaks
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine